Takeda Pharmaceutical’s Mimrylo is now approved for treating polycythemia vera, a rare blood cancer with limited therapeutic options. Originally developed by Protagonist Therapeutics, the engineered peptide gives Takeda a drug with blockbuster sales potential as the pharma company’s top overall product faces patent expirations.
The post First-in-Class Takeda, Protagonist Drug Lands FDA Approval in Rare Blood Disorder appeared first on MedCity News.
